LBF20303PG05: Difference between revisions

No edit summary
No edit summary
 
(6 intermediate revisions by the same user not shown)
Line 6: Line 6:
|LipidBank=XPR1705
|LipidBank=XPR1705
|LipidMaps=LMFA03010142
|LipidMaps=LMFA03010142
|SysName=9alpha,15S-dihydroxy-11-oxo-prosta-5Z,13E,17Z-trien-1-oic acid
|SysName=(9alpha,15S) -Dihydroxy-11-oxo-prosta- (cis-5,trans-13,cis-17) -trien-1-oic acid
|Common Name=&&Prostaglandin D_3&&9alpha,15S-dihydroxy-11-oxo-prosta-5Z,13E,17Z-trien-1-oic acid&&
|Common Name=&&Prostaglandin D_3&&(9alpha,15S) -Dihydroxy-11-oxo-prosta- (5Z,13E,17Z) -trien-1-oic acid&&
|Source=PGD3 is produced by the metabolism of EPA via the cyclooxygenase pathway.[[Reference:Kulkarni_PS:Kaufman_PL:Srinivasan_BD:,J. Ocul. Pharmacol.,1987,3,349|{{RelationTable/GetFirstAuthor|Reference:Kulkarni_PS:Kaufman_PL:Srinivasan_BD:,J. Ocul. Pharmacol.,1987,3,349}}]]
|Source=PGD3 is produced by the metabolism of EPA via the cyclooxygenase pathway.[[Reference:Kulkarni_PS:Kaufman_PL:Srinivasan_BD:,J. Ocul. Pharmacol.,1987,3,349|{{RelationTable/GetFirstAuthor|Reference:Kulkarni_PS:Kaufman_PL:Srinivasan_BD:,J. Ocul. Pharmacol.,1987,3,349}}]]
|Chemical Synthesis=
|Chemical Synthesis=
|Metabolism=
|Metabolism=
|Biological Activity=PGD3 has almost same ability to decrease systemic blood pressure in rats and to decrease intraocular pressure in rabbits.[[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790|{{RelationTable/GetFirstAuthor|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]][[Reference:Goh_Y:Nakajima_M:Azuma_I:Hayaishi_O:,Jpn. J. Ophthalmol.,1988,32,471|{{RelationTable/GetFirstAuthor|Reference:Goh_Y:Nakajima_M:Azuma_I:Hayaishi_O:,Jpn. J. Ophthalmol.,1988,32,471}}]][[Reference:Kulkarni_PS:Srinivasan_BD:,Invest. Ophthalmol. Vis. Sci.,1985,26,1178|{{RelationTable/GetFirstAuthor|Reference:Kulkarni_PS:Srinivasan_BD:,Invest. Ophthalmol. Vis. Sci.,1985,26,1178}}]] However, it is 3 to 5 times more potent than PGD2 in the inhibition of ADP-induced human platelet aggregation.
|Biological Activity=PGD3 has almost same ability to decrease systemic blood pressure in rats and to decrease intraocular pressure in rabbits.[[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790|{{RelationTable/GetFirstAuthor|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]][[Reference:Goh_Y:Nakajima_M:Azuma_I:Hayaishi_O:,Jpn. J. Ophthalmol.,1988,32,471|{{RelationTable/GetFirstAuthor|Reference:Goh_Y:Nakajima_M:Azuma_I:Hayaishi_O:,Jpn. J. Ophthalmol.,1988,32,471}}]][[Reference:Kulkarni_PS:Srinivasan_BD:,Invest. Ophthalmol. Vis. Sci.,1985,26,1178|{{RelationTable/GetFirstAuthor|Reference:Kulkarni_PS:Srinivasan_BD:,Invest. Ophthalmol. Vis. Sci.,1985,26,1178}}]] However, it is 3 to 5 times more potent than PGD2 in the inhibition of ADP-induced human platelet aggregation.[[Reference:Herschman_HR:,Biochim._Biophys._Acta,1996,1299,125|{{RelationTable/GetFirstAuthor|Reference:Herschman_HR:,Biochim._Biophys._Acta,1996,1299,125}}]] [[Reference:Smith_WL:Garavito_RM:DeWitt_DL:,J. Biol. Chem.,1996,271,33157|{{RelationTable/GetFirstAuthor|Reference:Smith_WL:Garavito_RM:DeWitt_DL:,J. Biol. Chem.,1996,271,33157}}]]
}}
}}


{{Lipid/Footer}}
{{Lipid/Footer}}

Latest revision as of 06:39, 8 November 2010

LipidBank Top
(トップ)
Fatty acid
(脂肪酸)
Glycerolipid
(グリセロ脂質)
Sphingolipid
(スフィンゴ脂質)
Journals
(雑誌一覧)
How to edit
(ページの書き方)


Upper classes: LB LBF



Prostaglandin D3
LBF20303PG05.png
Structural Information
(9α,15S) -Dihydroxy-11-oxo-prosta- (cis-5,trans-13,cis-17) -trien-1-oic acid
  • Prostaglandin D3
  • (9α,15S) -Dihydroxy-11-oxo-prosta- (5Z,13E,17Z) -trien-1-oic acid
Formula C20H30O5
Exact Mass 350.20932407
Average Mass 350.4492
SMILES C(=CC[C@@H](O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)C(C[C@@H]1O)=O)CC
Physicochemical Information
PGD3 is produced by the metabolism of EPA via the cyclooxygenase pathway. Kulkarni_PS et al.
PGD3 has almost same ability to decrease systemic blood pressure in rats and to decrease intraocular pressure in rabbits. Bundy_GL et al. Goh_Y et al. Kulkarni_PS et al. However, it is 3 to 5 times more potent than PGD2 in the inhibition of ADP-induced human platelet aggregation. Herschman_HR Smith_WL et al.
Spectral Information
Mass Spectra
UV Spectra
IR Spectra
NMR Spectra
Other Spectra
Chromatograms
Reported Metabolites, References
Biospecies ID Compound Name Reference Comment
n.a. LBF20303PG05 See above. Bundy_GL et al. 1983
n.a. LBF20303PG05 See above. Goh_Y et al. 1988
n.a. LBF20303PG05 See above. Herschman_HR 1996
n.a. LBF20303PG05 See above. Kulkarni_PS et al. 1987
n.a. LBF20303PG05 See above. Kulkarni_PS et al. 1985
n.a. LBF20303PG05 See above. Smith_WL et al. 1996